TriSalus Life Sciences Stock (NASDAQ:TLSI)
Previous Close
$3.60
52W Range
$3.50 - $10.42
50D Avg
$4.14
200D Avg
$6.31
Market Cap
$123.50M
Avg Vol (3M)
$35.30K
Beta
0.50
Div Yield
-
TLSI Company Profile
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.